BR0308870A - Composto, composição farmacêutica, processo para preparar um composto, uso de um composto, e método para tratar um distúrbio trombótico em um paciente - Google Patents

Composto, composição farmacêutica, processo para preparar um composto, uso de um composto, e método para tratar um distúrbio trombótico em um paciente

Info

Publication number
BR0308870A
BR0308870A BR0308870-7A BR0308870A BR0308870A BR 0308870 A BR0308870 A BR 0308870A BR 0308870 A BR0308870 A BR 0308870A BR 0308870 A BR0308870 A BR 0308870A
Authority
BR
Brazil
Prior art keywords
compound
patient
treating
preparing
pharmaceutical composition
Prior art date
Application number
BR0308870-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Robert Wiley
Gary Lowell Engel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0308870A publication Critical patent/BR0308870A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0308870-7A 2002-04-01 2003-03-24 Composto, composição farmacêutica, processo para preparar um composto, uso de um composto, e método para tratar um distúrbio trombótico em um paciente BR0308870A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36852302P 2002-04-01 2002-04-01
PCT/US2003/007794 WO2003084929A1 (en) 2002-04-01 2003-03-24 Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa

Publications (1)

Publication Number Publication Date
BR0308870A true BR0308870A (pt) 2005-01-04

Family

ID=28791889

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308870-7A BR0308870A (pt) 2002-04-01 2003-03-24 Composto, composição farmacêutica, processo para preparar um composto, uso de um composto, e método para tratar um distúrbio trombótico em um paciente

Country Status (24)

Country Link
US (1) US7166606B2 (cg-RX-API-DMAC7.html)
EP (1) EP1492767B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005531529A (cg-RX-API-DMAC7.html)
KR (1) KR20040094892A (cg-RX-API-DMAC7.html)
CN (1) CN1288135C (cg-RX-API-DMAC7.html)
AT (1) ATE303990T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003218147A1 (cg-RX-API-DMAC7.html)
BR (1) BR0308870A (cg-RX-API-DMAC7.html)
CA (1) CA2478340A1 (cg-RX-API-DMAC7.html)
CR (1) CR7497A (cg-RX-API-DMAC7.html)
DE (1) DE60301569T2 (cg-RX-API-DMAC7.html)
DK (1) DK1492767T3 (cg-RX-API-DMAC7.html)
EA (1) EA007300B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045329A (cg-RX-API-DMAC7.html)
ES (1) ES2248737T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040900B1 (cg-RX-API-DMAC7.html)
IL (1) IL164018A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009640A (cg-RX-API-DMAC7.html)
NO (1) NO20044688L (cg-RX-API-DMAC7.html)
NZ (1) NZ535402A (cg-RX-API-DMAC7.html)
PL (1) PL373066A1 (cg-RX-API-DMAC7.html)
UA (1) UA76849C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003084929A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200407418B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6834308B1 (en) 2000-02-17 2004-12-21 Audible Magic Corporation Method and apparatus for identifying media content presented on a media playing device
US7363278B2 (en) 2001-04-05 2008-04-22 Audible Magic Corporation Copyright detection and protection system and method
US8972481B2 (en) 2001-07-20 2015-03-03 Audible Magic, Inc. Playlist generation method and apparatus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2018093716A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011658A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
US7265121B2 (en) * 2001-07-26 2007-09-04 Eli Lilly And Company Chemical compounds

Also Published As

Publication number Publication date
CA2478340A1 (en) 2003-10-16
UA76849C2 (uk) 2006-09-15
HRP20040900B1 (en) 2006-02-28
WO2003084929A1 (en) 2003-10-16
EA007300B1 (ru) 2006-08-25
PL373066A1 (en) 2005-08-08
DE60301569D1 (de) 2005-10-13
KR20040094892A (ko) 2004-11-10
EA200401290A1 (ru) 2005-02-24
ZA200407418B (en) 2005-09-15
DK1492767T3 (da) 2005-11-28
EP1492767A1 (en) 2005-01-05
ES2248737T3 (es) 2006-03-16
US7166606B2 (en) 2007-01-23
HK1070363A1 (en) 2005-06-17
CR7497A (es) 2005-01-17
JP2005531529A (ja) 2005-10-20
HRP20040900A2 (en) 2004-12-31
WO2003084929A8 (en) 2004-05-21
NZ535402A (en) 2006-02-24
ATE303990T1 (de) 2005-09-15
AU2003218147A1 (en) 2003-10-20
MXPA04009640A (es) 2005-01-11
NO20044688L (no) 2004-10-29
ECSP045329A (es) 2004-11-26
CN1288135C (zh) 2006-12-06
DE60301569T2 (de) 2006-06-14
IL164018A0 (en) 2005-12-18
EP1492767B1 (en) 2005-09-07
US20050096328A1 (en) 2005-05-05
CN1642914A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
IL251185A0 (en) mek inhibitors and methods of using them
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MXPA05012247A (es) Derivados de bencimidazol nuevos.
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
ATE403426T1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
SE0302756D0 (sv) Novel Compounds
NO20052182L (no) Nye forbindelser
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
BR0011339A (pt) Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.